Media Library

How therapeutic peptides span replacement hormones, receptor agonists/antagonists, and investigational compounds.

Three-tier system used throughout the course: pivotal/regulatory, peer-reviewed clinical, mechanistic/preclinical.

Native GLP-1 (~2 min) → liraglutide (~13 h) → semaglutide (~7 d): how acylation and modifications extend duration of action.

GLP-1 and GIP release after a meal — pancreatic β-cell, α-cell, gastric, and CNS targets.

Glucose-dependent insulin release, glucagon suppression, gastric emptying, and central satiety pathways.

GHRH analogs (CJC-1295) vs ghrelin mimetics (ipamorelin): pulsatile vs sustained GH release.

Angiogenesis, NO pathway modulation, growth-factor receptor crosstalk — predominantly preclinical.

MC1R–MC5R targets: pigmentation, energy balance, sexual function, exocrine — and where bremelanotide and setmelanotide bind.

Pulsatile vs continuous GnRH stimulation, agonist flare, and antagonist suppression.

Regulatory landscape for compounded peptides in the United States.

One-page printable summary of the grading rubric used across the course.

Initiation, titration, MTC/pancreatitis screen, GI side-effect coaching.

When 503A is appropriate, when it isn't, and the 2023 Category 2 list.

PDF export of every module's takeaways, claims, and key references.